EMEA-001039-PIP03-17

Key facts

Invented name
  • Xeomin
  • Bocouture
Active substance
Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins
Therapeutic area
  • Neurology
  • Ophthalmology
Decision number
P/0338/2018
PIP number
EMEA-001039-PIP03-17
Pharmaceutical form(s)
  • Powder for solution for injection
  • Solution for injection in pre-filled syringe
Condition(s) / indication(s)
Treatment of hemifacial spasm
Route(s) of administration
Intramuscular use
Contact for public enquiries
Merz Pharmaceuticals GmbH

Tel.: +49 6915031
E-mail: contact@merz.de

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating